Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the increasing therapeutic resistance caused by novel mutations or activated bypass pathways has...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ge, Mao, Longfei, Deng, Wenjing, Xu, Shuxiang, Zhao, Jie, Yang, Jianxue, Yao, Kaitai, Yuan, Miaomiao, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776995/
https://www.ncbi.nlm.nih.gov/pubmed/35071184
http://dx.doi.org/10.3389/fchem.2021.789030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776995/
https://www.ncbi.nlm.nih.gov/pubmed/35071184
http://dx.doi.org/10.3389/fchem.2021.789030

Ejemplares similares